Latest Millennium Pharmaceuticals Stories

2014-06-02 08:32:06

Results show adding LBH589 to bortezomib and dexamethasone significantly improved PFS by 37%, meeting Phase III study primary endpoint1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial showing a 37% improvement in progression-free survival (PFS) when using the investigational compound LBH589 (panobinostat) in combination with bortezomib[*] and dexamethasone compared to treatment with the same regimen with placebo in patients with...

2014-05-28 12:31:07

LONDON, May 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Pancreatic Cancer - Pipeline Review, H1 2014http://www.reportbuyer.com/pharma_healthcare/treatments/pancreatic_cancer_pipeline_review_h1_2013.html Pancreatic Cancer - Pipeline Review, H1 2014 SummaryGlobal Markets Direct's, 'Pancreatic Cancer - Pipeline Review, H1 2014', provides an overview of the Pancreatic Cancer's therapeutic pipeline.This report provides comprehensive information on...

2014-04-07 16:25:29

SAN DIEGO, April 7, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the addition of Ian B. Walters, M.D., MBA., a translational oncology and immunology expert. Dr. Walters was most recently an executive at Bristol Myers Squibb (BMS) where he led oncology drug development programs, large international matrix teams, and strategic transactions. He...

2014-03-18 04:21:58

ZURICH, March 18, 2014 /PRNewswire/ -- Takeda Pharmaceuticals International GmbH ("Takeda") today announced that Giles Platford has been appointed Head of Commercial Operations, Emerging Markets, reporting to Christophe Weber, Chief Operating Officer of Takeda Pharmaceutical Company Limited as of April 1, 2014. In this role he will be responsible for leading the continued expansion of Takeda's commercial activities in this region, which comprises Russia-CIS, Latin...

2014-02-05 08:30:28

SAN DIEGO, Feb. 5, 2014 /PRNewswire/ -- Ambrx Inc. today announced the appointment of Barry Greene to its board of directors. Mr. Greene has more than 20 years of experience in the healthcare, pharmaceutical and biotechnology industries. He is currently president and chief operating officer of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), a leader in RNAi therapeutics. The appointment increases Ambrx's board membership to six. "Barry joins Ambrx's board at a very exciting time for...

2014-01-14 12:27:32

CAMBRIDGE, Mass., Jan. 14, 2014 /PRNewswire/ -- Moderna Therapeutics, the pioneer in developing messenger RNA (mRNA) Therapeutics(TM), a revolutionary treatment modality to enable the in vivo production of therapeutic proteins, announced today the creation of Onkaido Therapeutics, a new venture focused exclusively on developing mRNA-based oncology treatments. Onkaido Therapeutics will launch with $20 million in committed capital from Moderna. The new company will focus initially on 15...

Word of the Day
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.